Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal
Jazz Pharmaceuticals said it will seek FDA removal of the second-line indication for lurbinectedin (Zepzelca) in metastatic small-cell lung cancer. Jazz plans a labeling supplement submission in Q3 2026. The indication was accelerated in 2020. The phase 3 LAGOON trial failed its overall survival endpoint, with median OS 8.7 vs 10.7 months (HR 1.19) for monotherapy. First-line maintenance remains unchanged.
How this was made
The 30-second read
Why it matters
Jazz’s planned withdrawal of the second-line indication follows negative LAGOON phase 3 overall survival results, increasing the probability of label removal and associated commercial contraction.
Market read
A concrete FDA-labeling action request is being prepared after confirmatory trial failure, which can change the investable revenue outlook for Zepzelca’s second-line use.
What to watch
The article does not quantify revenue contribution from the second-line indication or timing of FDA action, which could moderate near-term earnings impact.
Background
Lurbinectedin (Zepzelca) received FDA accelerated approval in 2020 for second-line metastatic SCLC, contingent on confirmatory clinical benefit.
Ticker impact
Jazz plans to ask the FDA to remove lurbinectedin’s second-line SCLC indication after LAGOON phase 3 failed overall survival.
Near-term downside bias for JAZZ as investors price in reduced addressable use and potential revenue pressure.
The article describes a concrete FDA labeling-supplement plan tied to confirmatory-trial failure, which can directly reduce indicated use even if first-line maintenance remains intact.
Market effects
Highlights heightened post-accelerated-approval confirmatory-trial risk for oncology drugs, potentially pressuring similar SCLC/solid-tumor programs.
No specific regional impact described.
Primarily US FDA labeling and US oncology commercialization implications.
Counterpoint
Because the first-line maintenance indication is unaffected, investors may over-discount the total revenue impact versus the portion tied to second-line metastatic SCLC.
Key entities
- companyJazz Pharmaceuticals
Plans to request FDA removal of lurbinectedin’s second-line SCLC indication via a labeling supplement.
- druglurbinectedin (Zepzelca)
Oncology therapy whose second-line SCLC indication is targeted for removal after failed confirmatory trial.
- regulatorFDA
Agency expected to review and act on the labeling supplement for the second-line indication.
- clinical_trialLAGOON trial
Phase 3 postmarketing study that did not meet overall survival endpoint for lurbinectedin regimens versus control.
